About: Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Courtney Crim et al published January 2015 in Proceedings of the American Thoracic Society

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2015 (fr) наукова стаття, опублікована в січні 2015 (uk) im Januar 2015 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Courtney Crim et al published January 2015 in Proceedings of the American Thoracic Society (en)
publication date	wds:Q57955575-E3B8F9C4-BAD3-43D0-AC92-68D5C7C153EF
publication date	2015-01-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q57955575-01A59FB9-1003-49D3-A0D0-A03BC61278C4 wds:Q57955575-02583DAA-BE5C-4633-B57F-1357474F89C4 wds:Q57955575-0579DB09-4780-45C2-8D7D-D66DD8FCD92D wds:Q57955575-135264C8-2FDB-428F-A947-F90089D6FD27 wds:Q57955575-1B139BE0-A77E-49B4-857F-E13475CB6D30 wds:Q57955575-25E7C210-1DE0-4EB5-BA13-3F2527BE3E52 wds:Q57955575-2F2590BE-7F56-4A67-BF47-191CA4E89F41 wds:Q57955575-2F3852CB-E664-4981-A712-474F22F0615B wds:Q57955575-33D6AEBE-AA2A-4BDF-8E81-99422283079F wds:Q57955575-37903CBD-2E97-4AC8-BA87-1EE9B6B903B6 wds:Q57955575-384568E0-A26A-4BB1-AFAF-217A1F757AFD wds:Q57955575-4C4F2858-C497-444F-A94E-F5AAE0E17EEA wds:Q57955575-54DC5422-85CA-49CC-9C56-7FB9FADD0779 wds:Q57955575-608EE74E-0969-4095-8881-48D73B19345B wds:Q57955575-7EA742B8-8029-4FDF-AA0C-37B531045161 wds:Q57955575-7FDC95F2-3D5E-45B3-91E9-FE4D0B48ECB3 wds:Q57955575-825139F8-D085-4CAB-A8D3-4A2974BE342B wds:Q57955575-97D7E922-15DA-44C0-ADB1-608A8D00A25F wds:Q57955575-A2A2B8FC-D4E0-4A84-93C4-6D3E8F48F087 wds:Q57955575-AFF9D7C9-6946-4DBC-9753-0AF4EB5033B8 wds:Q57955575-B07641AA-4381-47D1-940E-9E2DBB2B367F wds:Q57955575-B441D2BD-14E4-4DCF-BD1E-2E940415FAA6 wds:Q57955575-C7F2E220-D5F9-41F8-A9F0-D4700B9C6392 wds:Q57955575-DBC00F54-A23C-4C08-8BDA-2C2CCFD350A3 wds:Q57955575-E9AEE1DD-BB84-4CD9-B76F-4514ACAD72DC wds:Q57955575-FE66269B-3E4B-4EA2-A6C7-79D9AFC7D3DC wds:Q57955575-FF3934B5-119C-443B-A2A3-570C1EC745AE wds:Q57955575-FFB33519-B53B-4231-B8F0-884AD6935D09
cites work	Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Reported pneumonia in patients with COPD: findings from the INSPIRE study Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study The burden of community-acquired pneumonia in seniors: results of a population-based study Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Spirometric reference values from a sample of the general U.S. population The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. Pneumonic vs nonpneumonic acute exacerbations of COPD. Clinical practice. Community-acquired pneumonia Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Risk factors for death and hospitalization from pneumonia. A prospective study of a general population Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.
author name string	wds:Q57955575-0283DAE6-D538-4547-8CAD-E3184C9EF8C6 wds:Q57955575-07197700-4A62-474B-8263-83B908C7021C wds:Q57955575-31181D5F-EB29-469C-9666-0E69A5C3E7F2 wds:Q57955575-45AE3922-8C2D-4684-ABD7-D08A9C6EDDEC wds:Q57955575-B074F2D3-1D5C-4A93-A081-588E50788173 wds:Q57955575-BF2F678F-D65C-4B0B-B145-88FBB34D647E wds:Q57955575-C7434148-18D3-4BD6-9C50-E5CFA0AACD6C wds:Q57955575-CED83D61-B383-4E4A-B1D4-8A853F450917 wds:Q57955575-FD82655F-0BA8-46BB-BD1F-D07639930269
author name string	Jean Bourbeau Courtney Crim Frank Barnhart Sally Lettis Donald A. Mahler Andrew Wachtel Mark T. Dransfield Paul W. Jones Peter M. A. Calverley
rdfs:label	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (en) Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (nl)
skos:prefLabel	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (en) Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (nl)
name	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (en) Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (nl)
author	wds:Q57955575-570AD9CF-CA44-4477-B564-FDCB7CCB3272 wds:Q57955575-AEFCA525-F5F6-4D15-81B7-A3184B62D65A wds:Q57955575-FF51DD88-328A-4389-9C4E-AA65F0A19228
author	Nicola A Hanania Fernando J Martinez Jørgen Vestbo
title	wds:Q57955575-A2F5919A-A344-4D7C-853E-97442767EAD8
title	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (en)
page(s)	wds:Q57955575-2C5BC4B4-8B9A-45EF-B757-82A671083690
page(s)	27-34
instance of	wds:Q57955575-44093CF0-5488-4E7D-A62B-10FCBD6B3CBC
instance of	scholarly article

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software